Drug intelligence / Profile preview

oleoylethanolamide + ginger extract + lavender essential oil

Development stage
Preclinical
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral, Topical, Inhalation
01

Overview

A combination dietary supplement consisting of **oleoylethanolamide** (OEA), **ginger extract**, and **lavender essential oil**, each with evidence for bioactivity in inflammation, oxidative stress, and mood regulation but not commonly marketed under a unified brand or fixed-dose formulation. - **Oleoylethanolamide** is an endogenous lipid mediator that acts primarily as a **peroxisome proliferator-activated receptor alpha (PPAR-α) agonist** and is implicated in the regulation of lipid metabolism, appetite, neuroprotection, and anti-inflammatory responses. Clinical studies in humans have shown supplementation with OEA decreases levels of inflammatory cytokines like IL-6 and TNF-α and reduces oxidative stress markers in obese individuals, likely via activation of PPAR-α, inhibition of NF-κB signaling, and suppression of downstream pro-inflammatory mediators[1]. - **Ginger extract** is derived from the root of **Zingiber officinale** and contains active compounds (e.g., gingerols, shogaols) with **anti-inflammatory**, antiemetic, analgesic, and antioxidant effects, targeting pathways such as COX, LOX, and NF-κB. - **Lavender essential oil** is a volatile oil from **Lavandula angustifolia** with a primary clinical profile as an **anxiolytic, sedative, mild analgesic, and anti-inflammatory** agent. It acts through several mechanisms, including modulation of GABAergic signaling and G protein-coupled receptors, and exerts topical antimicrobial and antioxidant activities[2][3][4][5]. This combination's potential uses may include adjunctive support for **obesity, inflammation, anxiety, and mood regulation**. Scientific research exists on the single components but not on the efficacy, safety, or regulatory status of this exact three-ingredient combination in a singular formulation.

02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)GABRR (GABA-A receptor subunit rho)NF-κBNMDAR (Glutamate receptor ionotropic, NMDA)PPARA (Peroxisome proliferator-activated receptor alpha)SERT (Sodium-dependent serotonin transporter)GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on oleoylethanolamide + ginger extract + lavender essential oil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on oleoylethanolamide + ginger extract + lavender essential oil.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call